Since our launch in 2014, Oak HC/FT has been focused on pursuing win-win opportunities across the entire healthcare spectrum. Oncology represents a particularly large and important area for our team and our resident oncologist, Zeke Emanuel, owing to the sector’s large scale combined with a host of factors driving change — including the rapid pace of pharmaceutical innovation, growing complexity of treatment pathways, and arduous prior-authorization processes for providers.
- The RELAY Trial: A “Race” Between Erlotinib Plus Ramucirumab vs. Erlotinib Plus Placebo in EGFR (+) Metastatic Non-Small Cell Lung Cancer (mNSCLC)
- Phase 3 Clinical Study Paves the Way for a New Subcutaneous Treatment for Multiple Myeloma
- Oncology Analytics Appoints David Fusari As Chief Technology Officer